Workflow
securities class - action
icon
Search documents
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-07-16 07:12
Core Viewpoint - The Schall Law Firm is investigating Gilead Sciences, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its HIV treatment trials [1][2]. Group 1: Investigation Details - The investigation centers on whether Gilead issued false or misleading statements or failed to disclose critical information to investors [2]. - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns, specifically a decrease in CD4+ T-cell and absolute lymphocyte counts in some trial participants [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to reach out for assistance [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Organon & Co. - OGN
GlobeNewswire News Room· 2025-07-16 02:19
Core Viewpoint - Investors have until July 22, 2025, to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for failing to disclose material information during the class period from November 3, 2022, to April 30, 2025 [1][3] Company Information - Organon & Co. is facing lawsuits for allegedly violating federal securities laws by not disclosing important information during the specified class period [3] - The company announced a significant reduction in its dividend payout from $0.28 to $0.02 on March 10, 2025, which contradicted previous assurances to investors about maintaining the dividend [4] Financial Impact - Following the announcement of the dividend cut, Organon's share price dropped over 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4] Legal Proceedings - The first filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322, with a subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanding the class period [5]
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC
GlobeNewswire News Room· 2025-07-16 00:22
Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly providing misleading information regarding its expected revenue and earnings during the Class Period from December 12, 2024, to June 30, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided investors with overly positive statements about enrollment and morbidity rates while concealing adverse facts about the company's true performance [5]. - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].
Shareholders who lost money on Red Cat Holdings, Inc. (NASDAQ: RCAT) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is July 22nd
GlobeNewswire News Room· 2025-07-15 20:34
Core Viewpoint - A securities class action lawsuit has been filed against Red Cat Holdings, Inc. for alleged misrepresentations regarding its production capacity and contract value, leading to significant financial harm for investors [1][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all persons or entities who purchased Red Cat securities [1]. - The class period for the lawsuit is from March 18, 2022, to January 15, 2025, with a lead plaintiff deadline of July 22, 2025 [7]. - Allegations include misrepresentations about the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract with the U.S. Department of Defense [7]. Group 2: Key Events Timeline - On July 27, 2023, Red Cat disclosed that the Salt Lake City Facility could only produce 100 drones per month, leading to an 8.93% stock drop to $1.02 on July 28, 2023 [7]. - On September 23, 2024, the company reported a Q1 FY2025 loss of $0.17 per share and revenue of $2.8 million, resulting in a 25.32% stock decline to $2.36 on September 25, 2024 [7]. - On November 19, 2024, Red Cat announced winning the SRR Contract, claiming potential revenues of $50–79.5 million for FY2025 [7]. - On January 16, 2025, a report from Kerrisdale Capital estimated the SRR Contract value at $20–25 million, causing the stock to fall 21.54% to $8.56 on January 17, 2025 [7]. Group 3: Impact of Allegations - The lawsuit claims that investors suffered significant financial harm due to alleged false or misleading statements made by Red Cat [7]. - Stock price declines are linked to corrective disclosures regarding the company's production capabilities and contract valuations [7].
ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit
Prnewswire· 2025-07-15 20:06
PHILADELPHIA, July 15, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company"). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program ...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG
GlobeNewswire News Room· 2025-07-15 17:03
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...
RBGLY DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reckitt Benckiser Group PLC Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RBGLY
GlobeNewswire News Room· 2025-07-15 16:50
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 and July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased Reckitt ADSs you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)
GlobeNewswire News Room· 2025-07-15 14:46
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/or ...
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-07-15 14:38
Core Viewpoint - The Schall Law Firm is investigating Harrow, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - Harrow, Inc. reported Q1 2025 financial results on May 8, 2025, with revenues that fell short of consensus estimates and an adjusted EBITDA of -$1.9 million [2]. - Following the announcement of these results, Harrow's shares experienced a decline of over 4% [2].
Faruqi & Faruqi Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Prnewswire· 2025-07-15 14:34
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LL ...